NOVO NORDISK INDIA PRIVATE LIMITED

Company Introduction: Novo Nordisk India Private Limited

Nature: Trader

Description:

Novo Nordisk India Private Limited is the Indian subsidiary of Novo Nordisk A/S, a leading global healthcare company with a century of innovation and leadership in diabetes care. Headquartered in Bengaluru, India, the company primarily focuses on the sales, marketing, and distribution of Novo Nordisk's wide range of pharmaceutical products across the Indian subcontinent. These products include innovative treatments for diabetes, obesity, hemophilia, and growth hormone-related disorders. While Novo Nordisk has extensive global manufacturing facilities, its operations in India are predominantly centered on commercial activities, making it a significant importer and distributor of its parent company's medicines. The company is committed to improving the lives of patients in India by ensuring access to advanced healthcare solutions and fostering local partnerships.

NOVO NORDISK INDIA PRIVATE LIMITED manufactures or sells products primarily in the areas of diabetes care, obesity, hemophilia, and growth disorders.

For diabetes care, their portfolio includes a range of insulin preparations such as Levemir, Novolog, Novorapid, Fiasp, Tresiba, Ryzodeg, and Novomix. They also offer GLP-1 receptor agonists like Ozempic, Victoza, and Rybelsus for the management of type 2 diabetes. Additionally, they provide Wegovy for chronic weight management.

In the field of rare blood and endocrine disorders, they supply products for hemophilia, including NovoSeven, Novoeight, and Refixia. For growth disorders, they offer Norditropin.